The global transplant diagnostics market size was valued at USD 500.1 million in 2016 and is likely to expand at a CAGR of 7.6% over the forecast period. Increasing organ transplants is a major factor driving demand for diagnostics used before the procedure. The demand for transplants has always been higher than the supply of organs. However, extensive research and analysis in the field to bridge this gap is likely to benefit the market.
Initiatives by the European Commission for organ harvesting have resulted in the availability of donated organs. The availability of the European donor card and increasing awareness among people have also augmented the organ donation rate in the region. Similarly, the U.S. has experienced considerable growth in organ donations due to rising awareness.
In addition, an increasing number of patients suffering from chronic diseases frequently leading to organ failure is creating an upsurge in demand for transplant procedures. Moreover, the adoption of stem cell therapy and personalized medicine is escalating. As a result, demand for pre-procedure diagnostics is growing swiftly. Risks and complexities associated with organ transplants necessitate the need for improved and sophisticated diagnostic tools.
Next Generation Sequencing (NGS) technology is rapidly replacing traditional diagnostic methods, such as serological techniques employed in Human Leukocyte Antigen (HLA) typing, owing to demand for high-throughput diagnostic tools with enhanced accuracy.
These pre-transplantation analysis techniques are employed to ensure safe and effective procedures. Factors such as growing awareness among physicians and the rapid adoption of technologically advanced tools are expected to drive growth in the future.
Molecular assays are preferred by physicians as compared to non-molecular assays. In addition, there has been a gradual shift in preference from serological assays to HLA typing owing to its benefits such as accuracy, efficacy, and lower risk. Currently, the PCR-based assay segment holds the largest market share owing to multiple applications.
The sequencing-based assay segment is expected to be the fastest-growing segment during the forecast period. The market growth may have a negative impact due to factors such as strict regulatory protocols, slower approval processes, poor reimbursement policies for organ transplants, and social and ethical controversies in different parts of the world.
Based on product, the transplant diagnostics market is segmented into reagents and consumables, instruments, and services and software. Manufacturers of these type of diagnostic products are adopting strategies such as purchase contracts for reagents and consumables. In addition, the key factor accelerating the adoption of reagents and consumables is their repeat purchase. As a result, the segment accounted for the largest revenue share in 2016 and is expected to retain its dominance during the forecast period.
The services and software segment is expected to follow reagents and consumables in terms of growth. The growth of this segment can be attributed to rise in the introduction of sophisticated instruments leading to increased demand for training sessions to educate technical staff regarding handling and usage. In addition, factors such as frequent software updates and improved services offered by market players to remain competent are driving the segment growth.
North America accounted for the largest revenue share in 2016. Major drivers include the high adoption of advanced techniques and diagnostic tools, higher healthcare expenditure, and availability of skilled professionals. The U.S. holds the largest market share owing to factors such as highly developed healthcare infrastructure and the availability of skilled professionals. Moreover, the high adoption of personalized medicines, stem cell therapies, and soft tissue transplants are augmenting the regional market growth.
On the contrary, regulations such as the Organ Transplantation Act that imposes restrictions on reimbursement policies for organ donors is negatively affecting the market. The existing demand and supply gap in organ donation and the availability of alternatives for heart and liver transplants is restraining the market growth.
The global market is highly competitive with very few players competing with each other in the international market. The quality and accuracy constraints of transplant diagnostic techniques like serology-based and PCR-based HLA typing increase the overall cost of products. As a result, players are implementing strategies, such as long-term contracts with diagnostic clinics and laboratories and discount pricing for bulk purchases.
Major market players include Thermo Fisher Scientific, Inc.; Illumina, Inc.; F. Hoffmann La-Roche AG.; Abbott Laboratories, Inc.; Qiagen N.V.; Immucor Transplant Diagnostics, Inc.; Bio-rad Laboratories, Inc.; Affymetrix, Inc.; and Omixon Ltd.
Attribute |
Details |
Base year for estimation |
2016 |
Actual estimates/Historical data |
2014 - 2015 |
Forecast period |
2017 - 2024 |
Market representation |
Revenue in USD Million & CAGR from 2017 to 2024 |
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
Country scope |
The U.S., Canada, The U.K., Germany, China, India, Brazil, Mexico, & South Africa |
Report coverage |
Revenue, company share, competitive landscape, growth factors, trends |
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2014 to 2024. For the purpose of this study, Grand View Research has segmented the global transplant diagnostics market report on the basis of technology, product, and region:
Technology Type Outlook (Revenue, USD Million, 2014 - 2024)
Molecular Assay
PCR-based Molecular Assay
Sequencing-based Molecular Assay
Non-molecular Assay
Serological Assay
Mixed Lymphocyte Culture Assay
Product Type Outlook (Revenue, USD Million, 2014 - 2024)
Reagents & Consumables
Instruments
Software and Services
Regional Outlook (Revenue, USD Million, 2014 - 2024)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
India
Latin America
Mexico
Brazil
Middle East & Africa
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.